Canada: CETA Trade Negotiations 2011 – Drug Market Exclusivity In The EU And Canada

Last Updated: October 25 2011

Article by Patrick E. Kierans , Kristin Wall and Jill Daley

A consideration of why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals

This briefing contributes to the current debate around IP rights for pharmaceuticals in Canada.

Against the backdrop of the CETA trade negotiations, Norton Rose Group's Toronto-based head of pharmaceuticals and life sciences, Patrick E. Kierans, and colleagues Kristin Wall and Jill Daley employ a comparative study to highlight why Canada should answer the European Union's call for heightened IP protection for pharmaceuticals.

On average, the EU is approving new drugs faster and enabling patent term restoration, leaving Canadian innovators doubly disadvantaged compared with their second-largest trading partner. Implementing patent term restoration and extending the term of data protection will help to level the playing field with Europe. For the majority of the sampled products, extending data protection by two years appears to provide greater security for innovators without extending overall IP exclusivity for innovative medicines. Increasing the rate of drug approval in Canada will diminish any market exclusivity impact of data protection and patent term restoration, while giving Canadians earlier access to new medicines.

See also our July 2011 briefing: "European Union – Canada debate IP rights for pharmaceuticals" (assessing proposed legal reforms).


Introduction

Canada and the European Union met in Ottawa this October for what may be the last full round of trade negotiations on the Comprehensive Economic and Trade Agreement (CETA). The issue of harmonizing European and Canadian intellectual property rights for pharmaceuticals remains open for negotiation.

Having already identified pharmaceutical IP rights as an area where Canada must improve, the EU has proposed three legal or regulatory reforms:

  • provide innovator companies with fair treatment under the Patented Medicines (Notice of Compliance) Regulations, namely providing innovators with the same effective right of appeal in court proceedings under these regulations that generic manufacturers have;
  • extend the term of data protection; and
  • implement patent term restoration (PTR).

This briefing focuses on the latter two reforms (data protection and PTR) as both reforms have the potential to affect drug market exclusivity in Canada. While important to innovators for greater market certainty, the proposed reform on effective innovator appeal rights is not specifically addressed as it does not directly impact overall drug market exclusivity, but rather acts as safeguard against a premature finding of patent invalidity or non-infringement.

Data protection and patent term restoration – Canada vs. EU

Data protection in Canada presently provides eligible innovative drugs with eight years of drug market exclusivity, with the possibility of a six-month extension for submitting pediatric trial data. Generic manufacturers are prohibited from filing a comparative drug submission relying, directly or indirectly, on the innovative drug's clinical trial data during the first six years of the eight-year term. No generic will be granted marketing approval until the applicable data protection term has expired.

Data protection in Europe operates similarly, except the total market exclusivity provided is typically 20 percent longer (i.e., 10 years in total with an eight-year no-filing period). An eleventh year of data protection can also be granted for approval of a new use, dosage form, etc.

PTR provides drug market exclusivity by accounting for some of the lost patent term benefit during a drug's development and regulatory approval phase. It is not unusual for a new drug to enter the Canadian market with less than half of its 20-year patent term remaining. PTR is available in Europe in the form of "supplementary protection certificates" (SPC). SPCs cannot restore more than five years to the patent and cannot extend a drug's remaining patent term beyond 14 years. Canada is one of the only developed countries that does not provide for any form of PTR.

A comparative look at drug market exclusivity in the EU (i.e., data protection, patent term, SPC) and Canada (i.e., data protection, patent term) supports the case for heightened data protection and PTR in Canada.

Methodology

In order to consider the impact of adopting the proposed IP reforms on data protection and PTR in Canada, the authors compared the total market exclusivity provided by data protection and patents for a sample of 22 drugs approved in both Canada and the EU.1 Specifically, the 22 candidate drugs were selected from Canada's Register of Innovative Drugs (Innovative Register), which listed (as of July 2011) 105 "innovative" human drugs granted data protection in Canada.

Twenty-two drugs were selected in order to obtain a 20 percent representative sample of the 105 drugs listed on the Innovative Register. Candidate drugs with the most recent approval dates were selected, and include products with significant IMS global sales.2

In order to assess the comparative drug market exclusivity provided by data protection and patents in Canada and Europe, candidate drugs were required to have: (1) data protection; (2) patents listed on the Canadian Patent Register; and (3) a central European market authorization.

The following data was collected for each candidate drug in both Canada and the EU:

  • date of market approval;3
  • data protection expiry date;4
  • earliest patent expiry date;
  • latest patent expiry date; 5 and
  • where applicable, the grant of an SPC.6

Findings

Slower Canadian drug approval times as compared with the EU make a strong case for implementing patent term restoration in Canada.

In 17 of the 22 candidate drugs considered (77%), drugs were approved earlier in the EU than in Canada: time differences ranged from five years (as with Abilify) to four months (as with Ilaris, Daxas). Of the sample drugs considered, Canadian drugs were approved an average of 451.4 days later than in the EU.

Since the date a new drug submission (NDS) is filed in Canada is generally not available in the public domain, we were not able to compare the relative speed of approval for the sample drugs selected. However, according to Health Canada's data on drug submission approval times, the median NDS approval time for 2010, including priority approvals, was 433 days – 1,563 days being the longest approval time and 216 days the shortest approval.7 Comparatively, the European Medicines Agency (EMA) annual report for 2010 states that the total average approval time for central European approvals granted in 2010 was 281 days.8 As a result, EU drugs were, on average, approved 152 days faster than the median Canadian approval.

Slower drug approval denies Canadians timely access to new medicines. Slower drug approval also reduces the patent term: drugs launched in Canada may have far less of the 20-year patent term remaining than drugs launched in the EU.

Canada already clearly stands out amongst virtually all OECD (Organisation for Economic Co-operation and Development) countries for failing to provide PTR. This briefing highlights the impact of this omission in the Canadian IP regime. EU drugs benefit from longer patent terms due to faster drug approval; as well as this, patent terms for EU drugs can be extended (for up to five years) to compensate for any portion of patent term lost for time spent in regulatory drug approval.

Implementing PTR in Canada would compensate in part for the patent term benefit lost due to Canada's slower rate of drug approval. Additionally, to the extent that Canada's approval times materially improve, the likelihood of any PTR being granted would decrease significantly.

Harmonization with the EU (i.e., extending data protection from eight years to 10 years in Canada) would not extend the total market exclusivity granted to Canadian drugs in the majority of cases.

Of the 22 drugs sampled, only eight Canadian drugs had total market exclusivity terms that would be extended were Canada to adopt the EU's data protection regime. This is because most of the candidate drugs considered had patent protection that extended beyond the term of data protection, meaning that the extension of data protection from eight years to 10 years in Canada would have no impact in the majority of cases.

In order to further verify this result, the authors considered all 105 of the human health drugs listed on Health Canada's Innovative Register. Of these drugs, 81 had patents listed on the Canadian Patent Register; 58 of 81 (72%) benefited from patent terms that extended beyond the data protection term. On average, the patent term for these 58 drugs extended 4.5 years past the data protection term.

With respect to the potential impact of PTR, only five of the 22 sampled products had been granted SPCs to date in Europe, which resulted in an average of two to three years of market time compensation for these five products.9

As a result, for drugs with data and patent protection in Canada, it may be concluded that total market exclusivity is governed primarily by the patent term, and not by the term of data protection. Here again, if Canadian drugs were approved faster, earlier approval dates would further diminish the impact of greater data protection market exclusivity over and above patent protection or any PTR.

Conclusion

A comparative look at 22 drugs approved in both the EU and Canada reveals that adopting the proposed CETA IP reforms will not automatically result in longer terms of drug market exclusivity. In many cases, the overall term of drug market exclusivity is governed by the 20-year patent term, which is the same in both Canada and the EU.

Canadian innovators are losing patent term benefit at the front end due to the length of time taken to comply with regulatory requirements. The EU is approving new drugs earlier and facilitating PTR, leaving Canadian innovators doubly disadvantaged, which has a significant impact on global marketing and R&D investment decisions. Implementing PTR is a necessary step to bring Canada up to the same level of patent protection as virtually all of its major trading partners. Extending the data protection term in Canada will provide innovators with more certainty, without extending market exclusivity beyond that already fixed by the patent term in the majority of the drugs considered. Substantially improving the rate of new drug approval in Canada will also diminish the market exclusivity impact of data protection over and above patent protection, at the same time granting Canadians earlier access to new medicines.

* This briefing does not constitute legal advice. The data collected on market exclusivity was done for the sole purpose of this briefing. The authors do not represent or warrant the applicability or expiry of any term of data protection, patent term or patent restoration term for the drugs considered.*

Footnotes

1 Sample drugs considered: Champix, Abilify, Cymbalta, Gardasil, Yondelis, Actemra/Ro-Actemra, Brilinta/Brilique, Ilaris, Prolia, Victoza, Votrient, Daxas, Kuvan, Jevtana, Byetta, Uloric/Adenuric, Gilenya, Cimzia, Banzel/Inovelon, Rapaflo/Silodyx/Urorex, Orencia, and Sprycel.

2 IMS, top-line market data, global and USA sales, accessed at: http://www.imshealth.com/portal/site/ims/menuitem.5ad1c081663fdf9b41d84b903208c22a/?vgnextoid=fbc65890d33ee210VgnVCM10000071812ca2RCRD&vgnextfmt=default (last accessed July 2011).

3 Canadian source: Health Canada, Register of Innovative Drugs, accessed at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/regist/index-eng.php ; EU source: European Medicines Agency, Database of Human Medicines, accessed at: www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landing_page.jsp&murl=menus/medicines/medicines.jsp&jsenabled=true.

4 Canadian source: Health Canada, Register of Innovative Drugs (as above); EU source: Unlike Canada, the EU does not maintain a public register of drugs eligible for data protection. The data protection expiry date was calculated by applying the relevant legislation. See Directive 2004/27/EC of March 31, 2004, and EMA procedural advice for users of the centralised procedure for generic/hybrid applications (January 2011). Based on the latter, the data protection expiry date in the EU was calculated as follows: (1) It was presumed that drugs granted data protection in Canada would also have been granted data protection in the EU; (2) 10 years were added to the date of the central marketing authorization to determine the data protection expiry date; (3) Based on drug approval information available on the EMA website, only one drug (Prolia/Xgeva) possessed a second approval that may have qualified for an 11th year of data protection.

5 Patent listing and expiry dates were obtained from the Canadian Patent Register located at: www.hc-sc.gc.ca/dhp-mps/prodpharma/patregbrev/index-eng.php. The equivalent EU patents were located with the Canadian Intellectual Property Office (CIPO) website, the European Patent Office website and QPAT located at: www.qpat.com/index.htm.

6 Information on supplementary protection certificates was obtained from the UK Patent Office at www.ipo.gov.uk/p-find-spc.htm.

7 Health Canada, Therapeutic Products Directorate Drug Submission Performance Annual Report January – December 2010 (May 16, 2011), page 16 (available from Health Canada on request).

8 European Medicines Agency, Annual Report 2010 (June 28, 2011), page 34, accessed at: www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/document_listing/document_listing_000208.jsp&mid=WC0b01ac058002933d&jsenabled=true.

9 Champix, Yondelis, Victoza, Banzel/Inovelon and Orencia.

Norton Rose OR LLP

Norton Rose OR LLP is a member of Norton Rose Group, a leading international legal practice offering a full business law service to many of the world's pre-eminent financial institutions and corporations from offices in Europe, Asia Pacific, Canada, Africa and the Middle East.

The Group's lawyers share industry knowledge and sector expertise across borders to support clients anywhere in the world. The Group is strong in financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and pharmaceuticals and life sciences.

Norton Rose Group has more than 2600 lawyers operating from 39 offices in Abu Dhabi, Amsterdam, Athens, Bahrain, Bangkok, Beijing, Brisbane, Brussels, Calgary, Canberra, Cape Town, Dubai, Durban, Frankfurt, Hamburg, Hong Kong, Johannesburg, London, Melbourne, Milan, Montréal, Moscow, Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome, Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from associate offices in Dar es Salaam, Ho Chi Minh City and Jakarta.

Norton Rose Group comprises Norton Rose LLP, Norton Rose Australia, Norton Rose OR LLP, Norton Rose South Africa (incorporated as Deneys Reitz Inc), and their respective affiliates.

On January 1, 2012, Macleod Dixon merges with Norton Rose OR, creating a global energy and mining powerhouse within Norton Rose Group. For more information, please visit nortonrose.com.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions